Vascepa Vs Placebo: AMRN Stands Behind REDUCE-IT Results
(RTTNews) – Amarin Corp. plc (AMRN), on Saturday, presented impressive primary results from its Vascepa cardiovascular outcomes trial, dubbed REDUCE-IT, at the 2018 Scientific Sessions of the American Heart Association in Chicago, Illinois.
See Original Article